CatalystMarker
← board

BTMD

distress 2/10 · well-funded / low risk
$2.33-1%today-49% from 52w high
biote.com223 employeesFounded 2012Irving, TXMedical Care Facilities
Revenue
$45M
Liquidity
$25M
Runway
—
Shares 1y
—

Price & events

+2.2% over 6M
$1.30$1.91$2.52Jan 26Apr 26Jul 263.3Mrating: Truist Securities: Buy (2026-04-16)rating: B. Riley Securities: Neutral (2026-03-12)rating: TD Cowen: Buy (2026-03-12)
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-2.1%
1W
+8.4%
1M
+5.0%
3M
+5.4%
6M
-45.0%
1Y
-70.8%
2Y
-76.1%
5Y
-76.8%
All

Overview

Volume
1.48K
52 Week Range
$1.30 – $4.55
Float Shares
19.63M
Short %
2.52%
% Held by Insiders
10.39%
% Held by Institutions
67.38%
RVOL
0.00x
Beta
1.66

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $3 (+17% upside) · 4 analysts
  • 2026-04-16Truist SecuritiesBuy
  • 2026-03-12B. Riley SecuritiesNeutral
  • 2026-03-12TD CowenBuy
  • 2025-08-07B. Riley SecuritiesBuy → Neutral
  • 2025-03-13Craig-HallumBuy
  • 2024-12-16Craig-HallumBuy

Competitors

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.